Join to view full profile
13400 E Shea BlvdScottsdale, AZ 85259
Phone+1 480-301-8000
Fax+1 602-301-8572
Dr. Singh is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Parminder Singh is an oncologist based in Scottsdale, AZ, with expertise in treating prostate, melanoma, kidney, bladder, and testicular cancers. He completed his fellowship in Hematology and Medical Oncology and his residency in Internal Medicine at Westchester Medical Center, after earning his medical degree from Maulana Azad Medical College in 2002. Dr. Singh's research work includes multiple publications in renowned journals on topics such as chemotherapy side effects and cost reduction in cancer drug therapy. He has also been a part of various clinical trials, taking on roles including Principal Investigator. His contributions involve the study of innovative treatments and therapies for different types of advanced cancers.
Education & Training
Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012- Westchester Medical CenterResidency, Internal Medicine, 2006 - 2009
Maulana Azad Medical CollegeClass of 2002
Certifications & Licensure
CA State Medical License 2012 - Present
AZ State Medical License 2012 - 2027
TX State Medical License 2011 - 2019
American Board of Internal Medicine Medical Oncology
Clinical Trials
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Sep 06
Publications & Presentations
PubMed
- 1 citationsIdeal candidates for bladder preservation in muscle-invasive bladder cancer.Japneet K Oberoi, Leslie K Ballas, Mark Tyson, Parminder Singh
Urologic Oncology. 2026-09-01 - 2 citationsTROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.Matthew D Galsky, Alexandra Drakaki, Arnab Basu, Bradley McGregor, Jens Bedke
Future Oncology. 2026-05-01 - 17 citationsReal-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis.Prateek Jain, Syed Arsalan Ahmed Naqvi, Nikita Tripathi, Japneet K Oberoi, Muhammad Abdullah Humayun
Clinical Genitourinary Cancer. 2025-12-01
Press Mentions
Treatment Device Posts “Highest Complete Response Rate Reported to Date” in Bladder Cancer TrialMay 4th, 2025- After Enfortumab Vedotin and Pembrolizumab for Advanced Bladder Cancer, What Next?April 22nd, 2025
OncLive® Presents State of the Science Summit™ on Genitourinary CancersOctober 15th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: